

This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Pharmaceuticals and Medical Devices Agency

## Summary of Investigation Results Axitinib

January 10, 2019

Non-proprietary name

Axitinib

Branded name (Marketing authorization holder)

Inlyta Tablets 1 mg, 5 mg (Pfizer Japan Inc.)

Indications Unresectable or metastatic renal cell carcinoma

## Summary of revisions

"Interstitial lung disease" should be added to the Clinically Significant Adverse Reactions section.

## Investigation results and background of the revision

Cases of interstitial lung disease have been reported in patients treated with axitinib in Japan. MHLW/PMDA concluded that revision of the package insert was necessary based on the results of their investigation of the currently available evidence and in consultation with expert advisors.

## Number of adverse reactions and patient mortalities reported in Japan during the previous 3 fiscal years

A total of 20 cases involving interstitial lung disease have been reported to date (including 2 cases for which a causal relationship with the product could not be ruled out.) One instance of patient mortality has been reported to date (a causal relationship with the product could not be established in this case.)

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>